Do you want to read an article? Please log in or register.
Effect of Finerenone on the KCCQ in Patients With HFmrEF/HFpEF: A Prespecified Analysis of FINEARTS-HF
Heart Failure
Related content
COMMENTED
Heart Failure
Finerenone and new-onset diabetes in heart failure: a prespecified analysis of the FINEARTS-HF trial
★ 1
Recommended and commented by
Prof. emer. Dr Ulrich Keller, Faculty Member
Lancet Diabetes Endocrinol
Butt JH, Jhund PS, Henderson AD, Claggett BL, Desai AS, Viswanathan P, Kolkhof P, Schloemer P, Amarante F, Lam CSP, Senni M, Shah SJ, Voors AA, Zannad F, Pitt B, Vaduganathan M, Solomon SD, McMurray JJV, FINEARTS-HF Committees and Investigators
doi: 10.1016/S2213-8587(24)00309-7
Heart Failure
Finerenone, chronic obstructive pulmonary disease, and heart failure with mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS-HF trial
Eur J Heart Fail
Butt JH, Jhund PS, Henderson AD, Claggett BL, Desai AS, Lam CSP, Mueller K, Scheerer MF, Viswanathan P, Senni M, Shah SJ, Voors AA, Zannad F, Pitt B, Vaduganathan M, Solomon SD, McMurray JJV
doi: 10.1002/ejhf.3661
Heart Failure
Estimated Long-Term Benefits of Finerenone in Heart Failure: A Prespecified Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial
JAMA Cardiol
Vaduganathan M, Claggett BL, Desai AS, Jhund PS, Lam CSP, Senni M, Shah SJ, Voors AA, Zannad F, Pitt B, Borentian M, Lay-Flurrie J, Viswanathan P, Behmenburg FU, McMurray JJV, Solomon SD
doi: 10.1001/jamacardio.2024.3782
Heart Failure
Finerenone and Outpatient Worsening Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial
JAMA Cardiol
Cunningham JW, Chatur S, Claggett BL, Vaduganathan M, Desai AS, Jhund PS, Llamas Esperón G, Lam CSP, Sato N, Senni M, Shah S, Voors A, Zannad F, Pitt B, Zieroth S, Brinker M, Rohwedder K, Kim SY, Lay-Flurrie J, Viswanathan P, McMurray JJV, Solomon SD
doi: 10.1001/jamacardio.2025.0016
Heart Failure
Finerenone in Women and Men With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial
JAMA Cardiol
Chimura M, Wang X, Jhund PS, Henderson AD, Claggett BL, Desai AS, Fonseca C, Goncalvesova E, Katova T, Mueller K, Glasauer A, Rohwedder K, Viswanathan P, Nodari S, Lam CSP, Saldarriaga CI, Senni M, Sharma K, Voors AA, Zannad F, Pitt B, Vardeny O, Vaduganathan M, Solomon SD, McMurray JJV
doi: 10.1001/jamacardio.2024.4613
Heart Failure
Finerenone Across the Spectrum of Kidney Risk in Heart Failure: The FINEARTS-HF Trial
JACC Heart Fail
Ostrominski JW, Mc Causland FR, Claggett BL, Desai AS, Jhund PS, Lam CSP, Senni M, Shah SJ, Voors AA, Zannad F, Pitt B, Schloemer P, Brinker M, Scheerer MF, McMurray JJV, Solomon SD, Vaduganathan M
doi: 10.1016/j.jchf.2025.03.006
Heart Failure
Finerenone and Atrial Fibrillation in Heart Failure: A Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial
JAMA Cardiol
Matsumoto S, Henderson AD, Jhund PS, Bauersachs J, Chioncel O, Claggett BL, Comin-Colet J, Desai AS, Filippatos G, Lam CSP, Pitt B, Scheerer MF, Lay-Flurrie J, Amarante F, Brinker M, Schou M, Senni M, Shah SJ, Voors AA, Zannad F, Zieroth S, Vaduganathan M, Solomon SD, McMurray JJV
doi: 10.1001/jamacardio.2025.0848
Heart Failure
Finerenone and New York Heart Association Functional Class in Heart Failure: The FINEARTS-HF Trial
JACC Heart Fail
Ostrominski JW, Vaduganathan M, Claggett BL, Desai AS, Jhund PS, Lam CSP, Senni M, Shah SJ, Voors AA, Zannad F, Pitt B, Borentian M, Rohwedder K, Lay-Flurrie J, Lavagnino MA, McMurray JJV, Solomon SD
doi: 10.1016/j.jchf.2025.03.007
Myocardial InfarctionTherapy and Intervention
Effect of Red Blood Cell Transfusion Strategy on Clinical Outcomes Among Patients with Acute Myocardial Infarction Undergoing Revascularization: A Prespecified Analysis of the MINT Trial
Circ Cardiovasc Interv
Rao SV, Brooks MM, D'Agostino HEA, Steg PG, Simon T, Aronow HD, Goldsweig AM, Malik S, Alsweiler C, Ho KK, Dehghani P, Caixeta A, Quraishi AR, Robinson S, Traverse JH, Siddiqi O, Fergusson DA, Potter BJ, Schulman-Marcus J, Keating FK, Carson JL, MINT Trial Investigators
doi: 10.1161/CIRCINTERVENTIONS.125.015249